Isolated hepatic perfusion for patients with liver metastases

Srinevas K. Reddy, Susan B. Kesmodel, H. Richard Alexander

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations

Abstract

Up to 80% of colorectal, melanoma, and neuroendocrine liver metastases are unresectable due to excessive tumor burden. Isolated hepatic perfusion (IHP) administers intensive therapy to the liver while limiting systemic toxicity and thus may have an important role in the management of unresectable liver metastases. This review s describes the development of IHP, initial clinical results, open and percutaneous IHP techniques, and contemporary long-term treatment outcomes. IHP with melphalan or tumor necrosis factor α (TNFα) has been shown to achieve hepatic response rates of greater than 50% with progression-free survival of greater than 12 months among patients with refractory ocular melanoma liver metastases. The only series describing outcomes of IHP for neuroendocrine liver metastases notes an overall response rate of 50% and a median actuarial overall survival of 48 months after IHP treatment with melphalan or TNFα. The majority of studies that have evaluated IHP have been performed in patients with colorectal cancer liver metastases (CRCLM). In aggregate, survival results from retrospective studies and phase I/II clinical trials suggest that IHP demonstrated no significant survival benefit compared with systemic chemotherapy alone as first-line therapy. In contrast, IHP does improve outcomes relative to that provided by second-line chemotherapy for CRCLM, with overall response rates of 60% and median duration of liver response of 12 months. Continued evaluation of IHP for unresectable liver metastases is necessary to establish its role in multidisciplinary treatment approaches.

Original languageEnglish (US)
Pages (from-to)180-194
Number of pages15
JournalTherapeutic Advances in Medical Oncology
Volume6
Issue number4
DOIs
StatePublished - Jul 2014
Externally publishedYes

Keywords

  • colorectal cancer liver metastases
  • isolated hepatic perfusion
  • melanoma liver metastases
  • neuroendocrine liver metastases
  • ocular melanoma

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Isolated hepatic perfusion for patients with liver metastases'. Together they form a unique fingerprint.

Cite this